The most commonly reported side effects of tildrakizumab include product dose omission issue, death, and psoriasis, based on 2,574 FDA adverse event reports from 2018 to 2025. 11.0% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for tildrakizumab.
These are voluntary reports and do not establish that tildrakizumab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside tildrakizumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
44.7% of tildrakizumab adverse event reports involve female patients and 43.4% involve male patients. The largest age group is elderly at 54%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking tildrakizumab when the adverse event was reported.
Showing 15 of 49 indications
Tildrakizumab is sold under the brand name Ilumya.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.